drugset / Trial / NCT00777361

Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy Volunteers

NCT00777361

Phase 1 Terminated 9 enrolled AstraZeneca
Non-randomizedCrossoverOpen-labelBasic science

Summary

This study is being performed in order to learn more about a new drug (possible as treatment for people with Alzheimer's Disease and other conditions with cognitive dysfunction (memory and attention problems)) and how it is handled by the body by giving the drug to healthy volunteers with different genotypes.

Timeline

Start
2008-10
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ispronicline Small molecule 25 mg Intravenous
Subject ispronicline Small molecule 50 mg Intravenous

Indications